NASDAQ:CLVS - Clovis Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.96 -0.30 (-1.97 %)
(As of 11/14/2018 02:25 PM ET)
Previous Close$15.26
Today's Range$14.36 - $15.71
52-Week Range$11.50 - $69.02
Volume48,215 shs
Average Volume4.16 million shs
Market Capitalization$763.27 million
P/E Ratio-2.87
Dividend YieldN/A
Beta2.07
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLVS
Previous Symbol
CUSIP18946410
Phone303-625-5000

Debt

Debt-to-Equity Ratio2.46
Current Ratio9.03
Quick Ratio8.46

Price-To-Earnings

Trailing P/E Ratio-2.87
Forward P/E Ratio-2.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$55.51 million
Price / Sales14.21
Cash FlowN/A
Price / CashN/A
Book Value$4.43 per share
Price / Book3.38

Profitability

EPS (Most Recent Fiscal Year)($5.12)
Net Income$-346,390,000.00
Net Margins-390.65%
Return on Equity-108.92%
Return on Assets-40.59%

Miscellaneous

Employees360
Outstanding Shares52,710,000
Market Cap$763.27 million
OptionableOptionable

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) announced its earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.60) by $0.11. The biopharmaceutical company had revenue of $22.76 million for the quarter, compared to analysts' expectations of $30.11 million. Clovis Oncology had a negative return on equity of 108.92% and a negative net margin of 390.65%. The business's revenue was up 35.4% on a year-over-year basis. During the same quarter last year, the business posted ($1.24) earnings per share. View Clovis Oncology's Earnings History.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Clovis Oncology.

What price target have analysts set for CLVS?

14 analysts have issued 12-month price targets for Clovis Oncology's shares. Their forecasts range from $16.00 to $110.00. On average, they expect Clovis Oncology's stock price to reach $57.0520 in the next year. This suggests a possible upside of 287.1% from the stock's current price. View Analyst Price Targets for Clovis Oncology.

What is the consensus analysts' recommendation for Clovis Oncology?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clovis Oncology.

What are Wall Street analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:
  • 1. Cann analysts commented, "The initial data for the TRITON2 study in patients with metastatic, HR-deficient, castration-resistant prostate cancer are based on small patient numbers, but are very encouraging for patients with BRCA mutations. The 44% ORR for these patients compares favorably to the reference literature. In addition, screening data using less invasive cfDNA plasma testing could help identify more patients eligible for Rubraca treatment in the prostate setting. We have not included any sales or earnings in our outlook from Rubraca in the prostate setting by 2022 due to its stage of development, but we are encouraged by these initial TRITON2 data. Our financial outlook for Clovis’ revenue remains unchanged for 2018-2022." (10/19/2018)
  • 2. According to Zacks Investment Research, "Clovis’ Rubraca is progressing well and registering sales growth. Nonetheless, Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, Clovis received approval for the label expansion in second-line maintenance setting in the United States, irrespective of BRCA-mutation, and as monotherapy in Europe. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. The company has stopped development of rociletinib upon receiving a CRL and lucitanib on negative results. Any further setback will adversely affect the company’s prospects. Moreover, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Meanwhile, Rubraca is set to face intense competition from currently marketed PARP inhibitors. Clovis’ shares have underperformed the industry so far this year." (7/10/2018)

Has Clovis Oncology been receiving favorable news coverage?

News coverage about CLVS stock has been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clovis Oncology earned a news impact score of 1.7 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days.

Who are some of Clovis Oncology's key competitors?

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (2.68%), Emerald Advisers Inc. PA (0.73%), Emerald Mutual Fund Advisers Trust (0.62%), State of New Jersey Common Pension Fund D (0.55%), Rice Hall James & Associates LLC (0.28%) and Prudential Financial Inc. (0.20%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.

Which institutional investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Los Angeles Capital Management & Equity Research Inc., C WorldWide Group Holding A S, Russell Investments Group Ltd., Wealthstreet Investment Advisors LLC, Rice Hall James & Associates LLC and Rhumbline Advisers. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.

Which institutional investors are buying Clovis Oncology stock?

CLVS stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Prudential Financial Inc., Hsbc Holdings PLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers Inc. PA, Fox Run Management L.L.C., University of Notre Dame DU Lac and Essex Investment Management Co. LLC. View Insider Buying and Selling for Clovis Oncology.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $14.74.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $763.27 million and generates $55.51 million in revenue each year. The biopharmaceutical company earns $-346,390,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clovis Oncology employs 360 workers across the globe.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is http://www.clovisoncology.com.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]


MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  432 (Vote Outperform)
Underperform Votes:  398 (Vote Underperform)
Total Votes:  830
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel